logo-loader
IXICO PLC - IXICO draws 104% upside estimate from Cavendish as tools expand IXICO draws 104% upside estimate from Cavendish as tools expand

IXICO PLC (LSE:IXI, OTC:PHYOF) imaging platform upgrade and two technology partnerships support...

4 hours, 2 minutes ago
Deep Dive

Scancell focuses on development of two critical cancer fighting assets

What the company does AIM-listed Scancell Holdings PLC's (LON:SCLP) primary focus is...

7 hours, 11 minutes ago
What Brokers Say

Convatec gets UBS backing as broker sees further upside after growth...

ConvaTec Group PLC (LSE:CTEC), the FTSE 100 medical products manufacturer, has retained a 'buy'...

22 hours, 17 minutes ago
What Brokers Say

AstraZeneca gets Jefferies backing as broker sees $80bn sales target within...

AstraZeneca PLC (LSE:AZN, NYSE:AZN), the FTSE 100 pharmaceuticals group, has received fresh...

22 hours, 47 minutes ago
What Brokers Say

Applied Nutrition's progress hailed by leading City bank

Applied Nutrition PLC (LSE:APN) price target rose to 370p from 350p at Deutsche Bank, which...

1 day, 22 hours ago

Scancell CEO on FDA breakthrough, melanoma survival data and Phase 3 plans

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about the company's latest clinical and regulatory progress, including FDA RMAT designation for its lead melanoma treatment, inzitagene plasmivec (iSCIB1+), updated survival data and...

2 hours, 2 minutes ago

Join Proactive

Get ahead of the curve